Form 4: Biote Corp. Director Receives Equity Grant
Director Equity Compensation Disclosure
Director Dana Lynn Jacoby was granted 37,777 deferred settlement RSUs and 130,000 stock options by Biote Corp.
Summary
- Director Dana Lynn Jacoby received an equity grant on May 12, 2026.
- The grant includes 37,777 Deferred Settlement RSUs, which are fully vested but deferred until 2027 or separation from service.
- The grant also includes 130,000 stock options with an exercise price of $2.20 per share.
- The stock options vest on the earlier of May 12, 2027, or the day before the 2027 Annual Meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of board leadership through multi-year vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of options and settlement of RSUs.
Risks
- Market price volatility affecting the value of the granted options.
- Dependence on continued service for the vesting of the 130,000 stock options.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity-based compensation for directors is standard practice in the biotechnology sector to ensure board alignment with long-term corporate performance and shareholder interests.
Comparison to Industry Standards
- The use of deferred settlement RSUs and time-vested options is consistent with standard corporate governance practices for mid-cap biotech firms.
- Vesting periods of one year for director options are common among peers in the healthcare and life sciences industries.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Update | Grant of equity to Director Dana Lynn Jacoby. | 05/12/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these equity instruments.
Next Steps
- Vesting of stock options on May 12, 2027.
- Settlement of RSUs in 2027 or upon separation from service.
Key Dates
| Date | Description |
|---|---|
| 05/12/2026 | Date of equity grant transaction. |
| 05/13/2026 | Date of filing. |
| 05/12/2027 | Vesting date for stock options. |
| 05/11/2036 | Expiration date for stock options. |
Keywords
Biote Corp, BTMD, Director Compensation, Equity Grant, Insider Transaction, Stock Options, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.